Articles producció científica> Medicina i Cirurgia

The Role of Biomarkers in Influenza and COVID-19 Community-Acquired Pneumonia in Adults

  • Identification data

    Identifier: imarina:9291908
    Authors:
    Carbonell, RMoreno, GMartín-Loeches, IBodí, MRodríguez, A
    Abstract:
    Pneumonia is a growing problem worldwide and remains an important cause of morbidity, hospitalizations, intensive care unit admission and mortality. Viruses are the causative agents in almost a fourth of cases of community-acquired pneumonia (CAP) in adults, with an important representation of influenza virus and SARS-CoV-2 pneumonia. Moreover, mixed viral and bacterial pneumonia is common and a risk factor for severity of disease. It is critical for clinicians the early identification of the pathogen causing infection to avoid inappropriate antibiotics, as well as to predict clinical outcomes. It has been extensively reported that biomarkers could be useful for these purposes. This review describe current evidence and provide recommendations about the use of biomarkers in influenza and SARS-CoV-2 pneumonia, focusing mainly on procalcitonin (PCT) and C-reactive protein (CRP). Evidence was based on a qualitative analysis of the available scientific literature (meta-analyses, randomized controlled trials, observational studies and clinical guidelines). Both PCT and CRP levels provide valuable information about the prognosis of influenza and SARS-CoV-2 pneumonia. Additionally, PCT levels, considered along with other clinical, radiological and laboratory data, are useful for early diagnosis of mixed viral and bacterial CAP, allowing the proper management of the disease and adequate antibiotics prescription. The authors propose a practical PCT algorithm for clinical decision-making to guide antibiotic initiation in cases of influenza and SARS-CoV-2 pneumonia. Further well-design studies are needed to validate PCT algorithm among these patients and to confirm whether other biomarkers are indeed useful as diagnostic or prognostic tools in viral pneumonia.
  • Others:

    Author, as appears in the article.: Carbonell, R; Moreno, G; Martín-Loeches, I; Bodí, M; Rodríguez, A
    Department: Medicina i Cirurgia
    URV's Author/s: Rodríguez Oviedo, Alejandro Hugo
    Keywords: Ventilator-associated pneumonia Sars-cov-2 Prognostic value Prognosis Procalcitonin concentrations Procalcitonin Marker Lower respiratory-tract Influenza pneumonia Infections Covid-19 Care Calcitonin-i gene C-reactive protein Biomarkers Bacterial respiratory co-infection Antibiotic-therapy
    Abstract: Pneumonia is a growing problem worldwide and remains an important cause of morbidity, hospitalizations, intensive care unit admission and mortality. Viruses are the causative agents in almost a fourth of cases of community-acquired pneumonia (CAP) in adults, with an important representation of influenza virus and SARS-CoV-2 pneumonia. Moreover, mixed viral and bacterial pneumonia is common and a risk factor for severity of disease. It is critical for clinicians the early identification of the pathogen causing infection to avoid inappropriate antibiotics, as well as to predict clinical outcomes. It has been extensively reported that biomarkers could be useful for these purposes. This review describe current evidence and provide recommendations about the use of biomarkers in influenza and SARS-CoV-2 pneumonia, focusing mainly on procalcitonin (PCT) and C-reactive protein (CRP). Evidence was based on a qualitative analysis of the available scientific literature (meta-analyses, randomized controlled trials, observational studies and clinical guidelines). Both PCT and CRP levels provide valuable information about the prognosis of influenza and SARS-CoV-2 pneumonia. Additionally, PCT levels, considered along with other clinical, radiological and laboratory data, are useful for early diagnosis of mixed viral and bacterial CAP, allowing the proper management of the disease and adequate antibiotics prescription. The authors propose a practical PCT algorithm for clinical decision-making to guide antibiotic initiation in cases of influenza and SARS-CoV-2 pneumonia. Further well-design studies are needed to validate PCT algorithm among these patients and to confirm whether other biomarkers are indeed useful as diagnostic or prognostic tools in viral pneumonia.
    Thematic Areas: Pharmacology, toxicology and pharmaceutics (miscellaneous) Pharmacology, toxicology and pharmaceutics (all) Pharmacology (medical) Pharmacology & pharmacy Microbiology (medical) Microbiology Infectious diseases General pharmacology, toxicology and pharmaceutics Engenharias ii Biochemistry
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: alejandrohugo.rodriguez@urv.cat
    Author identifier: 0000-0001-8828-5984
    Record's date: 2024-08-03
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/2079-6382/12/1/161
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Antibiotics. 12 (1):
    APA: Carbonell, R; Moreno, G; Martín-Loeches, I; Bodí, M; Rodríguez, A (2023). The Role of Biomarkers in Influenza and COVID-19 Community-Acquired Pneumonia in Adults. Antibiotics, 12(1), -. DOI: 10.3390/antibiotics12010161
    Article's DOI: 10.3390/antibiotics12010161
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Biochemistry,Infectious Diseases,Microbiology,Microbiology (Medical),Pharmacology & Pharmacy,Pharmacology (Medical),Pharmacology, Toxicology and Pharmaceutics (Miscellaneous)
    Ventilator-associated pneumonia
    Sars-cov-2
    Prognostic value
    Prognosis
    Procalcitonin concentrations
    Procalcitonin
    Marker
    Lower respiratory-tract
    Influenza pneumonia
    Infections
    Covid-19
    Care
    Calcitonin-i gene
    C-reactive protein
    Biomarkers
    Bacterial respiratory co-infection
    Antibiotic-therapy
    Pharmacology, toxicology and pharmaceutics (miscellaneous)
    Pharmacology, toxicology and pharmaceutics (all)
    Pharmacology (medical)
    Pharmacology & pharmacy
    Microbiology (medical)
    Microbiology
    Infectious diseases
    General pharmacology, toxicology and pharmaceutics
    Engenharias ii
    Biochemistry
  • Documents:

  • Cerca a google

    Search to google scholar